{"id":14107,"date":"2018-01-18T08:42:07","date_gmt":"2018-01-18T08:42:07","guid":{"rendered":"https:\/\/celonpharma.com\/?p=14107"},"modified":"2018-02-15T08:54:29","modified_gmt":"2018-02-15T08:54:29","slug":"completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/","title":{"rendered":"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial"},"content":{"rendered":"

Information received from the study centre confirms its course in accordance with the schedule and assumptions in terms of patient safety as defined in the clinical protocol approved by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. In the first part of the phase 1 trial were administered a drug dose provided for in the clinical protocol. An analysis of safety results and pharmacokinetic features will be used to select a drug administration regimen for the second part of the phase 1 trial.<\/p>\n

\n

Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:<\/strong> e will now be analysing data in order to establish the final drug administration regimen for the second part of the phase 1 trial. The current course of the trial and patient follow-up fully reflect the assumptions adopted by us in the clinical trial protocol both in terms of the participants’ safety and the schedule of the clinical programme.\n<\/p>\n<\/blockquote>\n

More information can be obtained by contacting:<\/p>\n

Current report<\/a>
\nPress release
\n<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Information received from the study centre confirms its course in accordance with the schedule and assumptions in terms of patient safety as defined in the clinical protocol approved by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. In the first part of the phase 1 trial were administered a drug doseRead more »<\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-14107","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"\nCompleted administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Information received from the study centre confirms its course in accordance with the schedule and assumptions in terms of patient safety as defined in the clinical protocol approved by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. In the first part of the phase 1 trial were administered a drug doseRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-18T08:42:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-02-15T08:54:29+00:00\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial\",\"datePublished\":\"2018-01-18T08:42:07+00:00\",\"dateModified\":\"2018-02-15T08:54:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/\"},\"wordCount\":183,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/\",\"name\":\"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2018-01-18T08:42:07+00:00\",\"dateModified\":\"2018-02-15T08:54:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/","og_locale":"en_US","og_type":"article","og_title":"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial - Celon Pharma","og_description":"Information received from the study centre confirms its course in accordance with the schedule and assumptions in terms of patient safety as defined in the clinical protocol approved by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. In the first part of the phase 1 trial were administered a drug doseRead more »","og_url":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/","og_site_name":"Celon Pharma","article_published_time":"2018-01-18T08:42:07+00:00","article_modified_time":"2018-02-15T08:54:29+00:00","author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial","datePublished":"2018-01-18T08:42:07+00:00","dateModified":"2018-02-15T08:54:29+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/"},"wordCount":183,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/","url":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/","name":"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2018-01-18T08:42:07+00:00","dateModified":"2018-02-15T08:54:29+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/completed-administration-of-the-esketamine-based-drug-to-all-subjects-of-the-first-part-of-the-phase-1-trial-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/14107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=14107"}],"version-history":[{"count":4,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/14107\/revisions"}],"predecessor-version":[{"id":14118,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/14107\/revisions\/14118"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=14107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=14107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=14107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}